Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis .

Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, Salmans JR, Barbour RM, Shughrue PJ, Nijjar T, Schenk D, Kinney GG, Zago W.

Amyloid. 2016 Sep;23(3):168-177. Epub 2016 Aug 5.

2.

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.

Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, Torres R, Tapia JR, Salmans J, Barbour R, Tam SJ, Flanagan K, Zago W, Kinney GG.

Amyloid. 2016 Jun;23(2):86-97. doi: 10.3109/13506129.2016.1148025. Epub 2016 Mar 16.

3.

Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.

Martin EB, Williams A, Wooliver C, Heidel RE, Adams S, Dunlap J, Ramirez-Alvarado M, Blancas-Mejia LM, Lands RH, Kennel SJ, Wall JS.

PLoS One. 2017 Mar 28;12(3):e0174152. doi: 10.1371/journal.pone.0174152. eCollection 2017.

4.

AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D.

PLoS One. 2012;7(12):e52686. doi: 10.1371/journal.pone.0052686. Epub 2012 Dec 26.

5.

Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Andrich K, Hegenbart U, Kimmich C, Kedia N, Bergen HR 3rd, Schönland S, Wanker E, Bieschke J.

J Biol Chem. 2017 Feb 10;292(6):2328-2344. doi: 10.1074/jbc.M116.750323. Epub 2016 Dec 28.

6.

Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.

Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M.

PLoS One. 2009;4(4):e5169. doi: 10.1371/journal.pone.0005169. Epub 2009 Apr 13.

7.

Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis.

Clos AL, Lasagna-Reeves CA, Kelly B, Wagner R, Wilkerson M, Jackson GR, Kayed R.

J Am Acad Dermatol. 2011 Nov;65(5):1023-31. doi: 10.1016/j.jaad.2010.09.735. Epub 2011 Jun 12.

PMID:
21669474
8.

Immunogold quantitation of immunoglobulin light chains in renal amyloidosis and kappa light chain nephropathy.

Silver MM, Hearn SA, Walton JC, Lines LA, Walley VM.

Am J Pathol. 1990 May;136(5):997-1007.

9.

Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.

Wall JS, Williams AD, Foster JS, Richey T, Stuckey A, Macy S, Wooliver C, Campagna SR, Tague ED, Farmer AT, Lands RH, Martin EB, Heidel RE, Kennel SJ.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10839-E10848. doi: 10.1073/pnas.1805515115. Epub 2018 Oct 30.

PMID:
30377267
10.

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.

Ami D, Lavatelli F, Rognoni P, Palladini G, Raimondi S, Giorgetti S, Monti L, Doglia SM, Natalello A, Merlini G.

Sci Rep. 2016 Jul 4;6:29096. doi: 10.1038/srep29096.

11.

Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.

Blancas-Mejía LM, Hammernik J, Marin-Argany M, Ramirez-Alvarado M.

J Biol Chem. 2015 Feb 20;290(8):4953-65. doi: 10.1074/jbc.M114.615401. Epub 2014 Dec 23.

12.

Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation.

Nieva J, Shafton A, Altobell LJ 3rd, Tripuraneni S, Rogel JK, Wentworth AD, Lerner RA, Wentworth P Jr.

Biochemistry. 2008 Jul 22;47(29):7695-705. doi: 10.1021/bi800333s. Epub 2008 Jun 26.

PMID:
18578541
13.

Al amyloidosis.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales.

Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Review.

14.

Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.

Laeng RH, Altermatt HJ, Scheithauer BW, Zimmermann DR.

Cancer. 1998 Jan 15;82(2):362-74.

PMID:
9445195
15.

Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody.

Wall JS, Kennel SJ, Paulus M, Gregor J, Richey T, Avenell J, Yap J, Townsend D, Weiss DT, Solomon A.

J Nucl Med. 2006 Dec;47(12):2016-24.

16.

Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Abraham RS, Geyer SM, Ramírez-Alvarado M, Price-Troska TL, Gertz MA, Fonseca R.

J Clin Immunol. 2004 Jul;24(4):340-53.

PMID:
15163890
17.

Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.

Bellotti V, Mangione P, Merlini G.

J Struct Biol. 2000 Jun;130(2-3):280-9. Review.

PMID:
10940232
18.

124I/125I-Fibril-reactive monoclonal antibody .

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2006 Dec 7 [updated 2008 Jan 2].

19.

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.

Klimtchuk ES, Prokaeva TB, Spencer BH, Gursky O, Connors LH.

Amyloid. 2017 Jun;24(2):115-122. doi: 10.1080/13506129.2017.1336996. Epub 2017 Jun 20.

20.

Supplemental Content

Support Center